摘要
目的：观察胎盘多肽注射液联合化疗对晚期非小细胞肺癌（NSCLC）生活质量及骨髓抑制的影响。方法：选取我院2011年1月-2012年5月收治的80例晚期NSCLC患者，随机分为观察组（胎盘多肽注射液联合化疗治疗组）和对照组（单纯化疗治疗组），各40例。两组均采用DP方案（多西他赛、顺铂），21d为1个周期，观察组加用胎盘多肽注射液治疗，每周期化疗前2d开始，连续静滴14d，2个周期后分析两组生活质量（Karnofsky评分）及骨髓抑制情况。结果：观察组治疗前后KPS评分比较差异有统计学意义（P〈0．05），且治疗后与对照组比较差异有统计学意义（P〈0．05）；化疗后与对照组比较，观察组白细胞和中性粒细胞下降，差异有统计学意义（P〈0．05），而血红蛋白和血小板下降差异无统计学意义（P〉0．05）。结论：胎盘多肽注射液联合化疗治疗晚期非小细胞肺癌在提高生活质量、减轻骨髓抑制方面有较好的临床疗效。
Objective： To observe the effect of placenta polypeptide injection combined with chemo- therapy on life quality of patients with advanced non-small cell lung cancer and its impact on bone marrow suppression. Methods. A total of 80 patients with advanced NSCLC admitted from January 2011 to May 2012 were selected and randomly divided into two groups by half： observation group （placenta polypeptide injection combined with chemotherapy） and control group （simple chemotherapy）. Patients in two groups all used DP schedule （hedorsey, cisplatin）, and 21 days was one course. Patients in treatment group had placenta polypeptide injection for 14 days, which started just Z days before each course of chemotherapy. Quality of life （Karnofsky score） and bone marrow suppression effect was analyzed after 2 courses. Re- suits： There was significant difference in KPS score before and after treatment in observation group （P〈 0.05）, and the difference was statistically significant between two groups after treatment （P〈0. 05）7 compared with control group, white blood cells and neutrophils were significantly decreased after chemo- therapy in treatment group （P〈0.05）, while differences in hemoglobin and platelet decline was no statis- tical significant （P〉0.05）. Gonclusion. Placenta polypeptide injection combined with chemotherapy is ef- fective in treating advanced non-small cell lung cancer, improving the quality of life, and reducing bone marrow suppression.
出处
《海南医学院学报》
CAS
2013年第12期1697-1699,共3页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210899)~~
关键词
胎盘多肽注射液
非小细胞肺癌
化疗
Placenta polypeptide injection
Chemotherapy
Non-small cell lung cancer
